Rubin EH - Search Results

1

Finding the right dose for cancer therapeutics--can we do better?

Rubin EH, Anderson KM. Rubin EH, et al. Clin Cancer Res. 2010 Feb 15;16(4):1085-7. doi: 10.1158/1078-0432.CCR-09-3246. Epub 2010 Feb 9. Clin Cancer Res. 2010. PMID: 20145182

2

Rendering the 3 + 3 Design to Rest: More Efficient Approaches to Oncology Dose-Finding Trials in the Era of Targeted Therapy.

Nie L, Rubin EH, Mehrotra N, Pinheiro J, Fernandes LL, Roy A, Bailey S, de Alwis DP. Nie L, et al. Among authors: rubin eh. Clin Cancer Res. 2016 Jun 1;22(11):2623-9. doi: 10.1158/1078-0432.CCR-15-2644. Clin Cancer Res. 2016. PMID: 27250933

3

The BATTLE trial: a bold step toward improving the efficiency of biomarker-based drug development.

Rubin EH, Anderson KM, Gause CK. Rubin EH, et al. Cancer Discov. 2011 Jun;1(1):17-20. doi: 10.1158/2159-8274.CD-11-0036. Epub 2011 Jun 1. Cancer Discov. 2011. PMID: 22586314

4

A 2-in-1 adaptive phase 2/3 design for expedited oncology drug development.

Chen C, Anderson K, Mehrotra DV, Rubin EH, Tse A. Chen C, et al. Among authors: rubin eh. Contemp Clin Trials. 2018 Jan;64:238-242. doi: 10.1016/j.cct.2017.09.006. Epub 2017 Sep 28. Contemp Clin Trials. 2018. PMID: 28966137

5

Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis.

Mukhopadhyay P, Ye J, Anderson KM, Roychoudhury S, Rubin EH, Halabi S, Chappell RJ. Mukhopadhyay P, et al. Among authors: rubin eh. JAMA Oncol. 2022 Sep 1;8(9):1294-1300. doi: 10.1001/jamaoncol.2022.2666. JAMA Oncol. 2022. PMID: 35862037 Free PMC article.

6

Advancing Clinical Trials to Streamline Drug Development.

Bates SE, Berry DA, Balasubramaniam S, Bailey S, LoRusso PM, Rubin EH. Bates SE, et al. Among authors: rubin eh. Clin Cancer Res. 2015 Oct 15;21(20):4527-35. doi: 10.1158/1078-0432.CCR-15-0039. Clin Cancer Res. 2015. PMID: 26473188 Free PMC article.

7

Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities.

Baik CS, Rubin EH, Forde PM, Mehnert JM, Collyar D, Butler MO, Dixon EL, Chow LQM. Baik CS, et al. Among authors: rubin eh. Clin Cancer Res. 2017 Sep 1;23(17):4992-5002. doi: 10.1158/1078-0432.CCR-16-3066. Clin Cancer Res. 2017. PMID: 28864727 Free PMC article.

8

Report on the Third FDA-AACR Oncology Dose-Finding Workshop.

Emens LA, Bruno R, Rubin EH, Jaffee EM, McKee AE. Emens LA, et al. Among authors: rubin eh. Cancer Immunol Res. 2017 Dec;5(12):1058-1061. doi: 10.1158/2326-6066.CIR-17-0590. Cancer Immunol Res. 2017. PMID: 29196440

9

From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.

Day D, Monjazeb AM, Sharon E, Ivy SP, Rubin EH, Rosner GL, Butler MO. Day D, et al. Among authors: rubin eh. Clin Cancer Res. 2017 Sep 1;23(17):4980-4991. doi: 10.1158/1078-0432.CCR-16-3064. Clin Cancer Res. 2017. PMID: 28864726 Free PMC article.

10

A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer.

Munster PN, Rubin EH, Van Belle S, Friedman E, Patterson JK, Van Dyck K, Li X, Comisar W, Chodakewitz JA, Wagner JA, Iwamoto M. Munster PN, et al. Among authors: rubin eh. Clin Cancer Res. 2009 Nov 15;15(22):7077-84. doi: 10.1158/1078-0432.CCR-09-1214. Epub 2009 Nov 3. Clin Cancer Res. 2009. PMID: 19887475 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

208 results

Search Page

Filters